8LBA Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinic
Darren Hodgson(AstraZeneca (United Kingdom)), M.J. O’Connor, Yanzheng Gu(Soochow University), W.H. Kim, Chris Harbron(Roche (United Kingdom)), J. Carl Barrett(National Institute of Environmental Health Sciences), Anne M. Dickinson(Newcastle University), Yung‐Jue Bang(Seoul National University), Alan Lau(AstraZeneca (United Kingdom)), L. Zhongwu, Anitra Fielding(AstraZeneca (United States)), H. Jones, Brian Dougherty(AstraZeneca (United States)), Chris Womack, S. Im, Martin G. McLoughlin, H.D. Mason, Xinsheng Yin, Jane Robertson(Cancer Research UK), Lenka Oplustilova(AstraZeneca (United Kingdom))
Cited by 0
Related Papers
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k